This specialized case study explores Kymanox’s approach to FDA deficiency resolution and Human Factors (HF) regulatory strategy through expert documentation review and submission optimization. Our team of Subject Matter Experts (SMEs) collaborated closely with client stakeholders to implement measurable improvements across Use-Related Risk Analysis (URRA), validation study remediation, Human Factors Engineering/Usability Engineering (HFE/UE) documentation, and deficiency response for connected pen injector and mobile application combination products.
CHALLENGE
SOLUTION
RESULTS
- Pharmaceutical client required efficient management and resolution of FDA deficiency letter addressing HF concerns for pen injector and mobile application system.
- Comprehensive HF regulatory strategy development needed to ensure successful FDA approval and market clearance.
- Expert review and remediation of existing HF documentation essential to effectively address FDA’s specific concerns and requirements.
- Strategic guidance required to strenghten HF submission addressing regulatory deficiencies while maintaining project timelines.
- Conducted comprehensive review of existing HF documentation including URRA, Instructions for Use (IFU), completed HF study data and root cause analysis.
- Provided expert recommendations on strategic next steps addressing FDA concerns and strenghtening regulatory submission.
- Reviewed HF validation study report and HFE/UE summary report ensuring submission effectively addressed all FDA deficiencies.
- Evaluated final FDA response for HF-related deficiencies, ensuring comrpehensive coverage of regulatory concerns and alignment with agency expectations.
- Leveraged deep FDA regulatory knowledge to optimize response strategy and documentation quality.
- Successfully achieved FDA approval in September 2022 through strategic deficiency resolution and comprehensive HF remediation.
- Efficiently managed FDA response process minimizing delays and maintaining project momentum toward market clearance.
- Delivered strengthened HF documentation and validation evidence satisfying FDA regulatory requirements for connected digital health combination product.